ArticleMolecular neurobiology2025
Identifying Immune Response Protein Biomarkers in Parkinson's-Related Cognitive Impairment and Depression.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of a robust multitarget protein panel for Parkinson's disease via absolute quantification and large-scale external replication.Brain communications · 2026Article
- Mechanisms Underlying Treatment-Resistant Depression: Exploring Sex-Based Biological Differences.Journal of neurochemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A distinct immune microenvironment may develop in patients with Parkinson's disease (PD), influenced by the severity of cognitive impairment and the presence of depression. We aimed to identify blood-based immune response markers in patients with PD using a proximity extension assay (PEA). Peripheral plasma samples from 58 patients with PD and 30 healthy controls (HCs) were analyzed for 92 immune response-associated proteins using Olink's PEA technology. A panel of four proteins (SIT1, CLEC4C, EIF5A, and NFATC3) was identified, effectively differentiating patients with PD from HCs, with a combined area under the receiver operating characteristic (ROC) curve of 0.863. Among these, ITGA11 and EIF5A were particularly associated with the degree of cognitive impairment. After applying Bonferroni correction, five proteins-PPP1R9B, MILR1, BTN3A2, IRAK1, and TANK-demonstrated potentially significant differences between depressed and non-depressed patients with PD-cognitively normal (PD-CN). In the correlation analyses, PPP1R9B exhibited a positive correlation with the Hamilton Depression Rating Scale (HAMD) score (r = 0.509, P = 0.019). Furthermore, after adjusting for potential confounding factors in binary logistic regression analysis, PPP1R9B remained significantly associated with depression (P = 0.042). We identified potential blood-based immune response markers associated with the severity of cognitive impairment and depression in patients with PD. These findings provide preliminary insights into the immune-related pathology underlying non-motor symptoms of PD, potentially guiding future studies aimed at targeted therapeutic strategies. Further validation in larger, independent cohorts is warranted to confirm these associations and their clinical utility.
Indexed as
Identifiers
40332667What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.